Imara sells PDE9 program (tovinontrine) to Cardurion for $35M upfront plus milestones

Enliven Therapeutics, Inc.

Upfront cash of $34.75M at closing plus $250K previously received; net proceeds ~$32.75M after ~$2M costs.
Potential milestone payments: $10M for clinical proof-of-concept, $50M for regulatory/commercial events.
Pro forma cash at Sep 30, 2022 rises to $82.2M; net loss for 9M 2022 falls from $30.7M to $13.0M.
R&D expenses eliminated from $18.8M to $1.1M for 9M 2022 as sold asset costs are removed.
Imara retains no further involvement in development or commercialization of the sold assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.